Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158.You must be logged in to view this page.
Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis StudyYou must be logged in to view this page.
Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 YearYou must be logged in to view this page.
Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated DiseasesYou must be logged in to view this page.
A patient-centric mission for life-changing autoimmune treatmentsYou must be logged in to view this page.
Artax Biopharma Expands Company’s Scientific Advisory Board and Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated DiseasesYou must be logged in to view this page.
Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated DiseasesYou must be logged in to view this page.